Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug

Fig. 4

The selectivity of presumed long-acting calcitonin hCTA. (A) Dose-range curves of rat calcitonin (rCT), rat amylin (rAMY), long-acting human calcitonin (hCTA), and KBP-336 on induction of β-arrestin in calcitonin receptor (CTR). (B) Amylin receptor type 3 (AMY3-R) using n = 6 per data point. (B) The mean percentage of C-terminal telopeptide I (CTX-I) in lean SD rats after a single injection with the vehicle, hCTA at 31 nmol/kg, 62 nmol/kg, 125 nmol/kg, or 250 nmol/kg, n = 8, 4, 7, 7, and 3 rats per group, respectively. (C) The mean food intake per animal after injection with the vehicle, hCTA at 62 nmol/kg, 125 nmol/kg, or 250 nmol/kg, n = 8, rats per group, except for 250 nmol/kg, n = 7. Error bars indicate the standard error of the mean

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us